Literature DB >> 16300642

3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.

Emmanuel Brouillet1, Carine Jacquard, Nicolas Bizat, David Blum.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by a mutation in the gene encoding Huntingtin. The mechanisms underlying the preferential degeneration of the striatum, the most striking neuropathological change in HD, are unknown. Of those probably involved, mitochondrial defects might play an important role. The behavioural and anatomical similarities found between HD and models using the mitochondrial toxin 3-nitropropionic acid (3NP) in rats and primates support this hypothesis. Here, we discuss the recently identified mechanisms of 3NP-induced striatal degeneration. Two types of important factor have been identified. The first are the 'executioner' components that have direct roles in cell death, such as c-Jun N-terminal kinase and Ca2+-activated protease calpains. The second are 'environmental' factors, such as glutamate, dopamine and adenosine, which modulate the striatal degeneration induced by 3NP. Interestingly, these recent studies support the hypothesis that 3NP and mutated Huntingtin have certain mechanisms of toxicity in common, suggesting that the use of 3NP might give new insights into the pathogenesis of HD. Research on 3NP provides additional proof that the neurochemical environment of a given neurone can determine its preferential vulnerability in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16300642     DOI: 10.1111/j.1471-4159.2005.03515.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  111 in total

Review 1.  Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration.

Authors:  Jorge M A Oliveira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

2.  pH as a biomarker of neurodegeneration in Huntington's disease: a translational rodent-human MRS study.

Authors:  Myriam M Chaumeil; Julien Valette; Céline Baligand; Emmanuel Brouillet; Philippe Hantraye; Gilles Bloch; Véronique Gaura; Amandine Rialland; Pierre Krystkowiak; Christophe Verny; Philippe Damier; Philippe Remy; Anne-Catherine Bachoud-Levi; Pierre Carlier; Vincent Lebon
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

Review 3.  Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death.

Authors:  Jaume Folch; Felix Junyent; Ester Verdaguer; Carme Auladell; Javier G Pizarro; Carlos Beas-Zarate; Mercè Pallàs; Antoni Camins
Journal:  Neurotox Res       Date:  2011-10-01       Impact factor: 3.911

4.  Acute and long-term response of dopamine nigrostriatal synapses to a single, low-dose episode of 3-nitropropionic acid-mediated chemical hypoxia.

Authors:  Cynthia A Crawford; Garnik Akopian; Justin Ring; Michael W Jakowec; Giselle M Petzinger; Julie K Andersen; Philip Vittozzi-Wong; Kristie Wang; Cristal M Farley; Sergios Charntikov; Danut Mitroi; M Flint Beal; Robert Chow; John P Walsh
Journal:  Synapse       Date:  2010-10-08       Impact factor: 2.562

5.  Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma.

Authors:  I Tasset; C Espínola; F J Medina; M Feijóo; C Ruiz; E Moreno; M M Gómez; J A Collado; C Muñoz; J Muntané; P Montilla; I Túnez
Journal:  J Physiol Biochem       Date:  2009-09       Impact factor: 4.158

Review 6.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 7.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

8.  Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

Authors:  N Klepac; M Relja; R Klepac; S Hećimović; T Babić; V Trkulja
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

Review 9.  Antioxidants in central nervous system diseases: preclinical promise and translational challenges.

Authors:  Chandrashekhar D Kamat; Sunyana Gadal; Molina Mhatre; Kelly S Williamson; Quentin N Pye; Kenneth Hensley
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

10.  L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway.

Authors:  Sumit Jamwal; Puneet Kumar
Journal:  Mol Neurobiol       Date:  2016-03-09       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.